Journal September 16, 2026 5 min read

Retatrutide: reported timelines in the literature

A research-supply catalogue summary of reported timelines for retatrutide (LY3437943), a triple GIP/GLP-1/glucagon receptor agonist, covering study durations and key findings from animal and human trials.

peptides-pro Editorial

Retatrutide, also known by the identifier LY3437943, is a synthetic triple receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors [1][3]. It is an investigational compound with no approved therapeutic indication; all available data derive from preclinical models and ongoing clinical trials. The evidence block does not provide sequence, molecular formula, or molecular weight for retatrutide.

The work centres on the GIP, GLP-1, and glucagon receptor families, which are involved in metabolic regulation, insulin secretion, and energy balance [1][4].

Research Studies

Retatrutide and metabolic parameters in diet-induced obese MASH mouse and hamster models

In diet-induced obese MASH mouse and hamster models, retatrutide was evaluated for efficacy on obesity-related endpoints [4]. In mice, retatrutide reduced body weight by 31% (p < 0.0001 vs. vehicle), affecting both fat and lean mass, and decreased food and water intake during the first days of treatment, while energy expenditure was not significantly altered. Retatrutide also markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content. In hamsters, retatrutide altered [data incomplete in evidence]. These findings are animal-only and do not establish effects in humans.

Retatrutide and renal fibrosis in UUO and aged mice

In a study comparing semaglutide, tirzepatide, and retatrutide, anti-fibrotic and anti-inflammatory effects were assessed in non-diabetic renal fibrosis using HK-2 cells and murine unilateral ureteral obstruction (UUO) and aging models [2]. Integrating in vivo and in vitro data showed model- and drug-specific patterns. In the UUO model, retatrutide effects were associated with concurrent inhibition of both PI3K-AKT and NF-κB pathways. In the aging model, [data incomplete in evidence]. These results are from preclinical models and cell culture; they do not demonstrate clinical outcomes.

Retatrutide and hypoglycemia recovery in type 2 diabetes mellitus

A clinical trial (NCT06982846) is investigating the effect of once-weekly retatrutide versus placebo on time to recovery from hypoglycemia during a hypoglycemic clamp in participants with type 2 diabetes mellitus following 16 weeks of treatment [7]. This study is ongoing; no results are reported in the evidence block.

Retatrutide and insulin secretion/sensitivity in type 2 diabetes mellitus

Another clinical trial (NCT06982859) aims to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment in adult participants with type 2 diabetes mellitus [8]. This study is ongoing; no results are available.

Retatrutide and body weight reduction in obesity or overweight

A clinical trial (NCT07232719) is evaluating the efficacy and safety of retatrutide compared with placebo for body weight reduction in participants with obesity or overweight [6]. Participation lasts about 65 weeks and may include about 18 visits. No outcomes are reported in the evidence block.

Retatrutide and dose escalation schemes in obesity or overweight without type 2 diabetes

A clinical trial (NCT07357415) is investigating the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight [5]. Participation lasts about 113 weeks. No results are available.

Retatrutide and pre-approval expanded access in severe obesity

An expanded access program (NCT07629401) provides pre-approval single-patient access to retatrutide for adults with severe obesity (BMI ≥35 kg/m²) and at least two serious or life-threatening obesity-related complications who are refractory to the best approved therapy and unable to participate in an ongoing clinical trial [3]. This is not a controlled study; no efficacy data are provided.

Retatrutide and cardiovascular risk biomarkers in adults with obesity with or without type 2 diabetes

In a post hoc analysis of phase 2 trials, lipoprotein and inflammatory biomarkers were assessed in adults with obesity/overweight with or without type 2 diabetes [10]. The evidence block does not provide specific results; this is a reference-only item.

Retatrutide and cognitive effects in diabetic rats

A study in diabetic rats examined retatrutide effects on cognition [12]. The evidence block does not provide specific findings; this is a reference-only item.

Retatrutide and product composition/labelling accuracy

An analysis of products sold as retatrutide in Australia examined composition and labelling accuracy [9]. The evidence block does not provide specific results; this is a reference-only item.

Retatrutide and a case report in type 1 diabetes with concurrent Shigella gastroenteritis

A case report described a man in his mid-30s with longstanding type 1 diabetes mellitus who developed complicating impending diabetic ketoacidosis after using online-sourced retatrutide [1]. The report notes that growing public interest in incretin-based therapies has led to increased availability of research peptides purchasable online, which may be used without medical assessment or counselling regarding adverse effects, sick-day management, or follow-up, and with uncertain composition, purity, and dosing accuracy. Retatrutide has no established role in type 1 diabetes mellitus. This is a single case report and does not establish causality or generalisable timelines.

Reported Timelines in Clinical Studies

The table below summarises the reported durations of participation in clinical studies of retatrutide as listed in the evidence block.

Study identifier	Population	Reported duration
NCT06982846	Type 2 diabetes mellitus	16 weeks of treatment [7]
NCT06982859	Type 2 diabetes mellitus	28 weeks of treatment [8]
NCT07232719	Obesity or overweight	About 65 weeks [6]
NCT07357415	Obesity or overweight without type 2 diabetes	About 113 weeks [5]

No timelines for onset of effect or recovery are provided in the evidence block for any study. The durations above refer to planned participation periods, not to observed outcomes.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.